Figure 5.

Siglec15 predicts the molecular subtype and the therapeutic response to several therapies in BLCA. (A-B) Correlations between Siglec15 and the pan-cancer T cell inflamed score and the individual genes included in the T cell inflamed signature. The T cell inflamed score is positively correlated with the clinical response to cancer immunotherapy. (C) Correlations between Siglec15 and molecular subtypes using seven different algorithms and bladder cancer signatures. (D-E) Mutational profiles of neoadjuvant chemotherapy-related genes in low- and high-Siglec15 groups. (E) Predictive accuracy of Siglec15 for molecular subtypes using seven different algorithms. The accuracy was equal to the area under the ROC curves. (F) Correlations between Siglec15 and the enrichment scores of several therapeutic signatures such as targeted therapy and radiotherapy. (G) Correlation between Siglec15 and the BLCA-related drug-target genes screened from the Drugbank database.